Overall, the in vivo and in vitro data further support that AMPK and Nrf2 are potential Lip-C6 “drug-able” target genes/proteins to treat NAFLD/NASH. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.